Latest News

Lilly invests further $5.3 bln in new Indiana website as obesity drug need skyrockets

Eli Lilly said on Friday it has invested another $5.3 billion in its new Lebanon, Indiana manufacturing plant, more than doubling its previous investment, as it scrambles to satisfy skyrocketing demand for its weightloss and diabetes drugs.

The brand-new financial investment, which brings the total to $9 billion, will help improve production of the active pharmaceutical components (API) for Lilly's powerful weight-loss drug Zepbound and diabetes treatment Mounjaro, the company stated.

Today's announcement tops the biggest manufacturing financial investment in our company's history and, we believe, represents the single largest financial investment in synthetic medicine API producing in U.S. history, said Lilly CEO David Ricks.

The Indianapolis-based company anticipates supply of Zepbound to stay quite tight in the near and midterm as it increases capability, it said on a financier call last month.

Lilly has actually dedicated an overall of $16 billion to constructing brand-new producing sites since 2020, including $2.5 billion for a. plant in Germany, and another $1.2 billion to update existing. centers, it said.

The business last month announced it will get a. production center from Nexus Pharmaceuticals to produce. injectable medicines.